UPDATE 2-EU backs AstraZeneca COVID-19 vaccine as blood clot reviews continue

UPDATE 2-EU backs AstraZeneca COVID-19 vaccine as blood clot reviews continue
Reuters
5 hrs ago
(Adds details)
April 23 (Reuters) - Europe's drug regulator reiterated on Friday the benefits of AstraZeneca's COVID-19 vaccine outweigh any risks, delivering an assessment based on continuing reviews into rare blood clots to help countries determine the shot's use.
The renewed backing comes after several countries in the European Union and worldwide have limited the use of the vaccine, known as Vaxzevria. Denmark has stopped its use altogether, after possible links to clotting issues in combination with low platelet levels were confirmed.
The interim analysis by a committee of the European Medicines Agency (EMA) determined that serious side effects of rare blood clots are likely to occur in 1 out of 100,000 vaccinated people, the regulator said in a statement.

Related Keywords

Bengaluru ,Karnataka ,India ,Denmark ,London ,City Of ,United Kingdom ,William Maclean ,Ludwig Burger ,Sriraj Kalluvila ,Saumyadeb Chakrabarty ,Josephine Mason ,Pushkala Aripaka ,Alistair Smout ,Peter Arlett ,Astrazeneca ,European Union ,European Medicines Agency ,Johnson ,Reuters ,Keith Weir ,பெங்களூரு ,கர்நாடகா ,இந்தியா ,டென்மார்க் ,லண்டன் ,நகரம் ஆஃப் ,ஒன்றுபட்டது கிஂக்டம் ,வில்லியம் மக்லேந் ,லுட்விக் பர்கர் ,ஜோசபின் கொத்தனார் ,ஐரோப்பிய தொழிற்சங்கம் ,ஜான்சன் ,ராய்ட்டர்ஸ் ,கேய்ட் வீர் ,